Lightcast Discovery

Market position

Private, venture-backed life science tools company in the single-cell analysis and functional screening segment, tracked with total funding of $81.5M and an estimated valuation of $38.42M as of April 2026. Listed comparables include Mission Bio, Singleron Biotechnologies and Atrandi Biosciences.

The company positions the platform around precise, light-directed control of droplet merging to create true single cell-cell interactions, the ability to run sequential merges for step-wise multi-parameter assays, throughput that avoids Poisson-limited loading efficiency, and real-time export of live cells of interest into standard well plates for downstream work. A portfolio of granted US patents covers droplet manipulation devices and methods, microfluidic analytical devices, microdroplet detection of cells and related probe chemistry.

Technology

Droplet microfluidics on microfabricated chips with optically mediated electrowetting-on-dielectric (oEWOD) droplet movement, enabling controlled and sequential droplet merging, microdroplet detection of cells, live cell dispensing and sorting into standard plate formats, and accompanying instrument control, data analysis and visualisation software.

Go-to-market

Direct engagement with researchers through an early access / evaluation programme for the Envisia platform, supported by scientific content marketing including peer-reviewed publications, white papers, posters and technical videos. Envisia entered limited commercial release in May 2025, with the 2025 Series B explicitly raised to fund commercialization.

Academic and translational researchers, and pharmaceutical and biotechnology drug discovery organisations working on antibody discovery, cellular therapies, immunotherapy, immuno-oncology, stem cell production and cell line development.

Geography

Headquartered at the Broers Building, JJ Thomson Avenue, Cambridge, CB3 0FA, United Kingdom.

History

Founded in 2019 in Cambridge, UK. The company raised £1.3m (USD 1.6m) in seed financing from private investors in September 2019 to expand pilot studies, launched a new website in November 2021, and subsequently raised Series A (2021), Series B and a further VC round. It announced a limited commercial release of the Envisia platform in May 2025, appointed Philip Binns as Chairman of the Board in June 2025, and added Brad Crutchfield as a board advisor in April 2026.

Risks & controversies

Sources conflict on basic firmographics: employee counts range from 98 to a "501-1000" listing, and funding-round dates differ between providers (a Series B is dated August 2023 in one dataset but announced May 30, 2025 in company and directory sources). The reported estimated valuation of $38.42M is below the reported $81.5M total raised, and valuation/round figures come from a secondary-market data provider rather than the company.